Research output per year
Research output per year
Personal profile
Expertises
Medical oncology; early clinical trials; genomic profiling
Main research areas
First-in-man phase I clinical trials, dose finding trials and other early clinical trials.
Current research
Genomic profiling including whole exome sequencing, SNP array, RNA sequencing of patients with solid tumours with the aim of optimizing the selection of patients for early clinical trials. Identification of driver mutations in circulating tumour DNA, monitoring of targeted therapy by tracking of driver mutations in circulating tumour DNA. Pharmacokinetics of novel anticancer drugs including drug-drug interactions. Pharmacodynamics of novel anticancer drugs in repeat biopsies. Patients’ decision-making when entering a phase I trial, and patients’ and their relatives’ perception of the information prior to enrolment.
Potential conflicts of interest
Consultant and adviser for the Danish Cancer Society. Member of the expert panel on experimental therapy under the Danish Medical Agency.
Fingerprint
Dive into the research topics where Morten Mau-Sørensen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours
Chen, X., Isambert, N., López-López, R., Giovannini, M., Pognan, N., Kapoor, S., Quinlan, M., You, B., Cui, X., Rahmanzadeh, G. & Mau-Sorensen, M., Mar 2023, In: British Journal of Clinical Pharmacology. 89, 3, p. 1046-1055 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
-
Harms of exercise training in patients with cancer undergoing systemic treatment: a systematic review and meta-analysis of published and unpublished controlled trials
Thomsen, S. N., Lahart, I. M., Thomsen, L. M., Fridh, M. K., Larsen, A., Mau-Sørensen, M., Bolam, K. A., Fairman, C. M., Christensen, J. F. & Simonsen, C., May 2023, In: EClinicalMedicine. 59, p. 101937 101937.Research output: Contribution to journal › Review › peer-review
-
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy
Borch, A., Bjerregaard, A-M., Araujo Barbosa de Lima, V., Østrup, O., Yde, C. W., Eklund, A. C., Mau-Sørensen, M., Barra, C., Svane, I. M., Nielsen, F. C., Funt, S. A., Lassen, U. & Hadrup, S. R., 2023, In: Frontiers in genetics. 14, p. 1058605 1058605.Research output: Contribution to journal › Journal article › Research › peer-review
-
Therapy with pembrolizumab in treatment-naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer
Eefsen, R. L., Larsen, J. S., Klarskov, L. L., Altaf, R., Høgdall, E., Ingeholm, P., Lykke, J., Nielsen, D. L., Pfeiffer, P., Poulsen, L. Ø., Qvortrup, C., Schou, J. V., Mau-Sørensen, M., Østerlind, K. & Jensen, B. V., 15 May 2023, In: International Journal of Cancer. 152, 10, p. 2145-2152 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
-
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Lassman, A. B., Wen, P. Y., van den Bent, M. J., Plotkin, S. R., Walenkamp, A. M. E., Green, A. L., Li, K., Walker, C. J., Chang, H., Tamir, S., Henegar, L., Shen, Y., Alvarez, M. J., Califano, A., Landesman, Y., Kauffman, M. G., Shacham, S. & Mau-Sørensen, M., 1 Feb 2022, In: Clinical Cancer Research. 28, 3, p. 452-460 9 p.Research output: Contribution to journal › Journal article › Research › peer-review
10 Citations (Scopus)